Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Boehringer Ingelheim
Merck
Harvard Business School
McKinsey

Last Updated: June 27, 2022

Investigational Drug Information for Palovarotene


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Palovarotene?

Palovarotene is an investigational drug.

There have been 10 clinical trials for Palovarotene. The most recent clinical trial was a Phase 2 trial, which was initiated on November 15th 2021.

The most common disease conditions in clinical trials are Myositis Ossificans, Exostoses, Multiple Hereditary, and Keratoconjunctivitis Sicca. The leading clinical trial sponsors are Clementia Pharmaceuticals Inc., Ipsen, and [disabled in preview].

There are twenty-three US patents protecting this investigational drug and two hundred and thirty-five international patents.

Recent Clinical Trials for Palovarotene
TitleSponsorPhase
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.IpsenPhase 3
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult SubjectsClementia Pharmaceuticals Inc.Phase 1
Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult SubjectsIpsenPhase 1

See all Palovarotene clinical trials

Clinical Trial Summary for Palovarotene

Top disease conditions for Palovarotene
Top clinical trial sponsors for Palovarotene

See all Palovarotene clinical trials

US Patents for Palovarotene

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Palovarotene See Plans and Pricing Therapeutic agent for keratoconjunctive disorders YAMAGUCHI UNIVERSITY (Yamaguchi, JP) See Plans and Pricing
Palovarotene See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Palovarotene See Plans and Pricing Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (Cambridge, MA) See Plans and Pricing
Palovarotene See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Palovarotene

Drugname Country Document Number Estimated Expiration Related US Patent
Palovarotene Australia AU2013342882 2032-11-08 See Plans and Pricing
Palovarotene Australia AU2018217197 2032-11-08 See Plans and Pricing
Palovarotene Brazil BR112015010428 2032-11-08 See Plans and Pricing
Palovarotene Canada CA2890424 2032-11-08 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Boehringer Ingelheim
Merck
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.